FindTrial
Sign In

A Non-interventional, multicentre study to see prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in India

A Non-interventional, multicentre study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in India ( BRCA Study) - BRCA Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/08/015338
Enrollment
240
Registered
2018-08-14
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ovarian, primary peritoneal and fallopian tube cancer patients

Interventions

None listed

Sponsors

AstraZeneca Pharma India Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who provide written informed consent 2. Female � 18 years of age 3. Previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients.

Exclusion criteria

Exclusion criteria: 1. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study 2. Patient participating in any other clinical study/ trial.

Design outcomes

Primary

MeasureTime frame
The proportion of previously and newly diagnosed ovarian, primary peritoneal or fallopian tube cancer patients with BRCA1 or BRCA2 mutations positive status.Timepoint: One day—

Secondary

MeasureTime frame
1. Level of association between histopathological type and BRCA 1/BRCA 2 mutation positive statusTimepoint: One day;2. To assess the association of BRCA1/BRCA2 mutation positive status and family history of breast and/or ovarian cancer and any cancer. ââ?¬Â¢ Patients having Family history of Ovarian cancer in first degree relative ââ?¬Â¢ Patients having family history of both Ovarian and breast cancer in first degree relative, ââ?¬Â¢ Patients having family history of breast cancer in first degree relative, ââ?¬Â¢ Patients having family history of Ovarian/other cancer before 45 years of age.Timepoint: NA;3. To determine the BRCA1/BRCA2 mutation distribution in Indian population.Timepoint: NA—

Countries

India

Contacts

Public ContactAmit Kumar

AstraZeneca Pharma India Ltd

rohit.kodagali@astrazeneca.com9820301179

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026